WO2014041551A1 - Formulation comprenant de l'imatinib sous la forme d'une solution orale - Google Patents

Formulation comprenant de l'imatinib sous la forme d'une solution orale Download PDF

Info

Publication number
WO2014041551A1
WO2014041551A1 PCT/IN2012/000614 IN2012000614W WO2014041551A1 WO 2014041551 A1 WO2014041551 A1 WO 2014041551A1 IN 2012000614 W IN2012000614 W IN 2012000614W WO 2014041551 A1 WO2014041551 A1 WO 2014041551A1
Authority
WO
WIPO (PCT)
Prior art keywords
aqueous solution
solution according
agent
weight
oral aqueous
Prior art date
Application number
PCT/IN2012/000614
Other languages
English (en)
Inventor
Durga Maheswari Parvataneni
Deepthi SOMA
Venkata Satya Narayana APPADWEDULA
Kali Satya Bhujanga Rao Adibhatla
Venkaiah Chowdary Nannapaneni
Original Assignee
Natco Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Limited filed Critical Natco Pharma Limited
Priority to PCT/IN2012/000614 priority Critical patent/WO2014041551A1/fr
Publication of WO2014041551A1 publication Critical patent/WO2014041551A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Definitions

  • the present invention is concerned with a stable oral aqueous solution comprising Imatinib or pharmaceutically acceptable acid addition salts or polymorphs thereof, process for preparing such solution and their use in the treatment of Chronic Myeloid Leukemia, Gastrointestinal Stromal Tumors and the like.
  • Imatinib mesylate is a protein-tyrosine kinase inhibitor; it inhibits the abnormal functioning Bcr-Abl tyrosine kinase, which is produced by the Philadelphia chromosome abnormality, found in chronic myeloid leukemia (CML). Imatinib inhibits cell proliferation and induces apoptosis (programmed cell death) in the Bcr-Abl cell lines and in the leukemic cells generated by CML. Imatinib also inhibits proliferation and induces apoptosis in gastrointestinal stromal tumor (GIST) cells, which express an activating c-kit mutation. More recently, the drug has been approved for the treatment of mesenchymal cell neoplasms of the intestinal tract.
  • GIST gastrointestinal stromal tumor
  • Imatinib mesylate can be used as a treatment for patients suffering from hepatic fibrosis based on its ability to downregulate stellate cell activation in culture and in vivo.
  • Imatinib mesylate is well absorbed after oral administration with C max achieved within 2- 4 hours post-dose. It was also reported that mean absolute bioavailability is 98%. Biotransformation of Imatinib mesylate is via hepatic metabolism and cytochrome P450 enzymes (especially CYP3A4). Imatinib mesylate is converted to its main circulating active metabolite, a N-desmethylated piperazine derivative. This derivative, in vitro, has potency similar to Imatinib mesylate and comprises about 15% of the AUC (area under the curve) for Imatinib mesylate.
  • the elimination half-lives of Imatinib mesylate and its major active metabolite, the N- desmethyl derivative are approximately 18 and 40 hours, respectively and the time to reach peak concentration is 2 to 4 hours.
  • Imatinib mesylate is presently available as tablet form of 100 mg and 400 mg.
  • the approved dosage range for imatinib mesylate in the treatment of CML is 400 mg to 800 mg (400 mg twice a day) and 600 mg per day for gastrointestinal stromal tumors (GIST).
  • amounts of imatinib mesylate effective to treat hepatic fibrosis would broadly range between about 50 mg and about 600 mg per day and preferably between about 50 mg and about 200 mg per day administered orally.
  • EP 0564409 patent discloses the preparation of [(4-(4-methylpiperazin-l-ylmethyl)-N-4- [methyl-3-(4-pyridin-3-yl) pyrimidin-2-yl amino) phenyl] benzamide (Imatinib) and the use thereof especially as an antitumor agent.
  • U.S. Patent publication no. 20060173182 corresponding PCT application no. PCT/GB04/00018 discloses process of preparing Imatinib.
  • US patent no. 5521184 disclosed 'Pyrimidine derivatives and process for the preparation thereof and in equivalent applications in other countries.
  • the above patent provides method of preparation of formulation of conventional tablets comprising active ingredient, wheat starch, lactose, colloidal silicic acid, talc and magnesium stearate.
  • the US Patent publication no. 20050143389 disclosed a method of treating of hepatic fibrosis with imatinib mesylate.
  • WO 06/040779 discloses gastric floating matrix formulation containing Imatinib, which provides in a single dose to float for a period of 12 hours.
  • the oral solution dosage form can be a viable alternative for patients who have problems in swallowing the tablet dosage form. It provides assurance of dosage uniformity upon administration to patients and eliminates difficulty of administration. An oral solution can also provide physicians more flexibility in designing dosage regimens for patients. Imatinib oral solution is suitable for administration to both pediatric and geriatric patients while also compensating for a good organoleptic properties and remaining suitably stable. Hence the development of a liquid oral formulation is therefore desirable since it offers improved patient compliance.
  • oral solution dosage forms are generally preferred to be in form of a solution. None of the above said prior arts discloses and/or envisages an oral solution hence the above drawback was contemplated in our invention.
  • Imatinib mesylate is having all the above favorable features suitable to formulate an oral solution, the work on present invention was taken up.
  • the present invention relates to design and development of an oral solution containing Imatinib mesylate and a process for its preparation, indicated for the treatment of newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in chronic phase, accelerated phase, blast crisis and GIST.
  • CML chronic myeloid leukemia
  • the main objective of the present invention is to design and develop an oral solution containing Imatinib or its pharmaceutically acceptable salts and polymorphs such as ⁇ , ⁇ or a 2 thereof for the treatment of CML, GIST and the like.
  • Another objective of this invention is to provide an alternative dosage form to existing tablets.
  • Another objective of the present invention is to provide a liquid composition which is amenable to high concentrations of Imatinib, is stable.
  • Another objective of the present invention is to provide uniform distribution of the active agent with a palatable taste. Another objective of this invention is to provide a desirable oral formulation for the treatment of small children and elderly patients to swallow easily.
  • Yet another objective of the present invention is to provide simple process for the preparation of a stable aqueous formulation of Imatinib.
  • Yet another objective of the present invention is to reduce the fluctuations in blood plasma concentration by giving a uniform liquid dosage form and enhancing patient compliance.
  • further objective of this invention is to provide the pharmaceutical composition of an oral solution to achieve better therapeutic levels for the therapy against aforementioned diseases.
  • the objective of the present invention is to develop a process for preparing the oral solution comprising active ingredient, diluents, cosolvents, buffering agents, sweetening agents, coloring agents, flavoring agents and chelating agents.
  • the main embodiment of the present invention is to design and develop a stable aqueous oral formulation that can be swallowed easily and comprising Imatinib including its pharmaceutically acceptable salts and polymorphs thereof, a process for its preparation, where in the said formulation has pH in the range of about 2 to 5.5 for the treatment of CML, GIST and the like in small children and elderly patients.
  • An aqueous solution for oral administration in humans comprising of therapeutically effective amount of Imatinib or its pharmaceutically acceptable salts and polymorphs thereof, one or more diluents, water miscible solvents, viscosity regulating agent, stabilizing agent, preservatives, buffering agents, chelating agent, antioxidant, sweetening agent, flavoring agent and coloring agent with a pH ranging from 2 to 5.5; intended to treat Chronic Myeloid Leukemia, Gastrointestinal Stromal Tumor.
  • the formulation of the present invention comprises wherein the oral solution contains a therapeutically effective pharmaceutical ingredient, Imatinib or its pharmaceutically acceptable salts and polymorphs such as ⁇ , ⁇ or a 2 used in the range of about 0.1 % to about 30% by weight relative to the total weight of the composition.
  • the diluent in the formulation of the present invention as used herein refers to an agent or mixture of agents, when added to a formulation makes the formulation thicker or less concentrated and may also improve manufacturability. Diluents of the present invention can also serve other functions. For example a diluent can also serve as a bulk sweetener.
  • Representative diluents include, but are not limited to, sucrose, sorbitol, xylitol, maltitol, dextrose, fructose, liquid glucose and mixtures thereof.
  • a preferred diluent of the present invention is sucrose.
  • the diluent used either single or in combinations in the range of about 5% to about 80% by weight relative to the total weight of the composition.
  • the solvents or cosolvents in the present invention may include but not restricted to water, ethanol, polyethylene glycols (PEG), propylene glycol, glycerin, sorbitol, benzyl alcohol and the like. Solvents or cosolvents of the present invention can also serve other functions. For example a solvent or cosolvent can enhance palatability.
  • a preferred solvent or cosolvent of the present invention is glycerin.
  • the solvent or cosolvent used either single or in combinations in the range of about 1% to about 40% by weight relative to the total weight of the composition.
  • the formulation of the present invention may include an appropriate amount of viscosity regulating agents; effective to stabilize the pharmaceutically active agent within the aqueous composition or used to increase the viscosity of the solution.
  • a viscosity regulating agents of the present invention may include but not restricted to one or more of polymeric materials preferably polyvinyl pyrrolidone and hypromellose.
  • viscosity regulating agents include polyacrylate and polyacrylate copolymer resins, celluloses and cellulose derivatives for example methyl-, ethyl- and propyl celluloses; hydroxyalkyl-celluloses, hydroxyl propyl celluloses, hydroxylpropylalkyl celluloses and the like including xanthan gum, polyvinyl resins, polyethylene glycol, polyethylene oxide, sorbitol, sucrose, xylitol, dextrose, fructose, maltitol, sugar, sodium alginate and the like.
  • the viscosity regulating agents used either single or in combinations in the range of about 0.05% to about 10% by weight relative to the total weight of the composition.
  • the formulation of the present invention may include an appropriate amount of stabilizing agents for the production of aqueous solution.
  • a preferred stabilizing agent of the present invention may include but not restricted to aminoacids such as glutamic acid, cysteine, glycine and the like.
  • the stabilizing agent used either single or in combinations in the range of about 0.1% to about 3% by weight relative to the total weight of the composition.
  • the formulation of the present invention may include an appropriate amount of chelating agents in a suitable concentration range to stabilize the product during storage.
  • a preferred chelating agent of the present invention may include disodium edetate and the like.
  • agents may include but not restricted to edetic acid, tartaric acid, malic acid, citric acid and salts thereof.
  • the chelating agent used either single or in combinations in the range of about 0.01% to about 5% by weight relative to the total weight of the composition.
  • compositions of the present invention may include an appropriate amount of sweeteners used for better patient acceptability of the dosage form and also enhances the flavor system. Additionally sweetening agents are conveniently employed in low concentrations.
  • a preferred sweetening agent of the present invention may include sucralose and the like.
  • non-limiting examples of sweeteners may include but not restricted to saccharin, sodium saccharin, potassium saccharin, cyclamate, sodium cyclamate, aspartame, sucralose, thaumatin, acesulfame potassium, altitame, neotame, xylose, ribose, mannose, galactose, neohesperidin dihydrochalcone and the like.
  • the sweetening agent used either single or in combinations in the range of about 0.01% to about 5% by weight relative to the total weight of the composition.
  • compositions of the present invention may include an appropriate amount of preservatives to prevent growth of micro organisms.
  • a preferred anti microbial agents of the present invention is selected from the group of methyl paraben, propyl paraben or salts and the like.
  • other preservatives include but not restricted to butyl paraben, ethyl paraben, benzoic acid and its derivatives such as sodium benzoate, benzyl alcohol, sorbic acid, potassium sorbate, benzalkonium chloride and the like.
  • the preservatives used either single or in combinations in the range of about 0.005% to about 1% by weight relative to the total weight of the composition.
  • compositions of the present invention may include an appropriate amount of antioxidants in a suitable concentration range to prevent oxidation.
  • a preferred antioxidant of the present invention may include sodium metabisulfite.
  • agents include but not restricted to ascorbic acid, sodium sulfite, sodium bisulfate, sodium thiosulfate, sodium ascorbate, sodium formaldehydesulfoxylate, malic acid, alkyl gallates like propyl gallate, lauryl gallate, or octyl gallate.
  • compositions of the present invention may include an appropriate amount of buffering agents to adjust the pH of the solution.
  • the solutions according to present invention have a pH of about 2 to 5.5.
  • a preferred buffering agent of the present invention is selected from citric acid, sodium citrate or mixture thereof.
  • other agents include but not restricted to phosphoric acid, succinic acid, tartaric, lactic acid, acetic acid and salts thereof, sodium hydroxide, sodium phosphate, sodium chloride, disodium hydrogen phosphate, sodium hydrogen carbonate, mono sodium phosphate, monopotassium phosphate, potassium citrate and mixtures thereof.
  • compositions of the present invention may include an appropriate amount of pharmaceutically acceptable color to provide a product with a more aesthetic and/or distinctive appearance.
  • other agents includes natural or synthetic dyes but not restricted to Carmoisine, FD&C Yellow No.5, FD&C Yellow No.6, FD&C Red No.3, FD&C Red No.20, FD&C Blue No.2, D&C Green No.5, D&C orange No.5, D&C Red No.8, caramel and the like.
  • the coloring agents used either single or in combinations in the range of about 0.001% to about 2% by weight relative to the total weight of the composition.
  • compositions of the present invention comprise neutraceutically acceptable flavoring agents to impart a pleasant flavor and often odor to a pharmaceutical preparation and can enhance patient compliance by making the composition more palatable.
  • non-limiting examples of flavoring agents may include but not restricted to cherry, vanilla, honey, lemon, strawberry, raspberry, black current, caramel chocolate, mint cool, fantasy flavor, bubble gum, citrus, lemon, lime, apple, apricot, peppermint, spearmint peach, pear, plum flavor and the like.
  • the flavoring agent used either single or in combinations in the range of about 0.01% to about 10% by weight relative to the total weight of the composition.
  • An aqueous solution may further include one or more pharmaceutically acceptable additives.
  • An aqueous solution of the present invention is easily administrable for pediatric and geriatric patients and thus patient compliance can be achieved.
  • the present invention containing pharmaceutical active agent equivalent to base is present at concentrations of 100 mg per 5 mL, 400 mg per 5 mL, 600 mg per 5 mL and 800 mg per 5 mL may be prepared with the above mentioned excipients using different proportions.
  • a pharmaceutical composition of the present invention may be used in the treatment of the human or animal body by therapy.
  • a process for the preparation of an aqueous oral solution comprising a therapeutically effective amount of Imatinib or its pharmaceutically acceptable salts and polymorphs thereof, mixing with one or more diluents in water followed by addition of water miscible solvent, a viscosity regulating agent, stabilizing agent, preservatives, buffering agents, chelating agent, antioxidant, sweetening agent, flavoring agent and coloring agent, where in the said solution has a pH from 2 to 5.5.
  • Imatinib mesylate and other polymorphs such as ⁇ , ⁇ or a 2 thereof, required as a daily dose in treatment will vary not only with the route of administration, the nature of the disease condition being treated and the age, weight and condition of the patient will ultimately be at the discretion of the attendant physician.
  • a suitable daily dose for use in treatment of Chronic Myeloid Leukemia, Gastrointestinal Stromal Tumors and the like will generally be in the same range. It may be appropriate to administer the required dose as two, three, four or more sub doses at appropriate intervals throughout the day.
  • the formulations of the present invention were found to be stable throughout the stability testing storage period.
  • Figure 1 shows the bioavailability study of the formulation of the present invention and tablet dosage form of Imatinib.
  • the components illustrated by the examples 1 to 25 are expressed in % by weight based on each composition.
  • the present invention provides a process for preparation of a composition, which comprises intimately mixing Imatinib with water miscible solvent containing preservatives followed by the addition of syrup base, viscosity regulating agent, buffering agent, flavoring agent, sweetener, coloring agent, chelating agent and an antioxidant for the intimate mixing until a clear solution is obtained or as mentioned under individual examples.
  • compositions of Example 1 to 25, contains the
  • Example 1 Example 2 Example 3 Example 4
  • Sorbitol solution (70% w/v) 0.00 40.00 0.00 20.00
  • Citric acid monohydrate 0.20 0.20 0.20 0.20 0.20 0.20
  • Purified water (qs to 100% w/v) as needed as needed as needed as needed as needed as needed as needed
  • Syrup base was prepared by dissolving sucrose in purified water.
  • Methyl paraben and propyl paraben were dissolved in glycerin under continuous stirring with application of heat; the solution is left to cool at room temperature and added to step (1).
  • step (3) Polyvinylpyrrolidone, sodium metabisulfite and disodium edetate were dissolved in purified water under continuous stirring and added to step (2); pH of the solution was adjusted to a desired value as needed by adding citric acid monohydrate and sodium citrate dihydrate.
  • Sorbitol solution (70% w/v) in an amount of 40% w/v and 20% w/v was added in the example 2 and 4 respectively.
  • Citric acid monohydrate 0.20 0.20 0.20 0.20 0.20 0.20
  • Citric acid monohydrate 0.20 0.20 0.20 0.20 0.20 0.20
  • Purified water (qs to 100% w/v) as needed as needed as needed as needed as needed as needed as needed
  • Citric acid monohydrate 0.20 0.20 0.20 0.20 0.20 0.20
  • Methyl paraben 0.00 0.18 0.18 0.18
  • Purified water (qs to 100% w/v) as needed as needed as needed as needed as needed as needed as needed
  • Malic acid was used as an antioxidant in example 13.
  • Citric acid monohydrate 0.20 0.20 0.20 0.20 0.20 0.20
  • Methyl paraben 0.00 0.00 0.18 0.00
  • Purified water (qs to 100% w/v) as needed as needed as needed as needed as needed as needed as needed
  • Sorbitol solution (70% w/v) 0.00 20.00 10.00 0.00 0.00 -
  • Citric acid monohydrate 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20
  • Disodium edetate 0.00 0.10 0.10 0.10 0.10
  • Pirie apple flavor 0.10 0.00 0.00 0.00 0.00
  • the plasma kinetics of the oral solution as described in above mentioned examples have been compared with those of the Imatinib tablets (manufactured using pharmaceutically acceptable additives) in a comparative study.
  • This comparative study was carried out with wistar albino rats; weighing 150-210 grams which were divided into different sets of study (two rats in each set) and fasted overnight prior to dosing, but were permitted water ad libitum. Both formulations were administered at the dose of 20 mg/kg body weight.
  • Blood samples were collected by puncturing retero-orbital sinus of the anaesthetized rats (with anesthetic ether) at different intervals post administration. Blood collection was done in prefilled heparin centrifugation tubes.
  • the aforementioned table gives an account of the bioavailability (AUC, C max ) of the Imatinib tablet dosage form and formulation in the present invention.
  • ADVANTAGES OF THE INVENTION a) Oral solution of a phenylaminopyrimidine derivative for example Imatinib is prepared which is used as BCR-ABL tyrosine kinase inhibitor for the treatment of Chronic Myeloid Leukemia, Gastrointestinal Stromal Tumors and the like.
  • Patient compliance can be achieved with the oral solution as it is easy to be administered so particularly preferable in pediatric and geriatric patients.
  • Imatinib oral solution can be viable alternative to patients who cannot swallow solid dosage forms.

Abstract

La présente invention concerne une solution pharmaceutique adaptée à l'administration orale contenant une quantité efficace d'imatinib y compris ses sels pharmaceutiquement acceptables et ses polymorphes tels que α, β ou α2 pour améliorer l'uniformité de dosage, la sapidité et ainsi l'observance par le patient. L'invention concerne en outre un procédé de préparation d'une formation orale aqueuse stable qui peut être avalée facilement et qui comprend un ingrédient actif en une concentration efficace pour une meilleure thérapie, notamment pour le traitement de la leucémie myéloïde chronique, des tumeurs stromales gastro-intestinales et équivalents, chez les petits enfants et les patients âgés.
PCT/IN2012/000614 2012-09-14 2012-09-14 Formulation comprenant de l'imatinib sous la forme d'une solution orale WO2014041551A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IN2012/000614 WO2014041551A1 (fr) 2012-09-14 2012-09-14 Formulation comprenant de l'imatinib sous la forme d'une solution orale

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2012/000614 WO2014041551A1 (fr) 2012-09-14 2012-09-14 Formulation comprenant de l'imatinib sous la forme d'une solution orale

Publications (1)

Publication Number Publication Date
WO2014041551A1 true WO2014041551A1 (fr) 2014-03-20

Family

ID=47178256

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2012/000614 WO2014041551A1 (fr) 2012-09-14 2012-09-14 Formulation comprenant de l'imatinib sous la forme d'une solution orale

Country Status (1)

Country Link
WO (1) WO2014041551A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019021229A1 (fr) 2017-07-26 2019-01-31 Ftf Pharma Private Limited Formes galéniques liquides d'imatinib
WO2019162756A3 (fr) * 2018-02-20 2019-10-31 Ftf Pharma Private Limited Compositions pharmaceutiques liquides de médicaments anticancéreux
WO2021009686A1 (fr) 2019-07-15 2021-01-21 Intas Pharmaceuticals Ltd. Composition pharmaceutique d'imatinib
CN114306342A (zh) * 2020-09-30 2022-04-12 江苏先声药业有限公司 一种注射用伊马替尼盐的药物组合物及其制备方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564409A1 (fr) 1992-04-03 1993-10-06 Ciba-Geigy Ag Dérivés de pyrimidine et procédé pour leur préparation
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
WO1999003854A1 (fr) 1997-07-18 1999-01-28 Novartis Ag Modification de la forme cristalline d'un derive n-phenyl-2-pyrimidineamine, procede de preparation et d'utilisation de ce dernier
US20050143389A1 (en) 2003-12-19 2005-06-30 Mount Sinai School Of Medicine Of New York University Treatment of hepatic fibrosis with imatinib mesylate
WO2006040779A2 (fr) 2004-10-11 2006-04-20 Natco Pharma Limited Formule à matrice flottante gastrique à libération contrôlée contenant la substance imatinib
US20060173182A1 (en) 2003-02-18 2006-08-03 Cipla Limited Process of preparing imatinib and imatinib prepared thereby
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20090238884A1 (en) * 2008-03-21 2009-09-24 Elan Pharma International Limited Compositions for site-specific delivery of imatinib and methods of use
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564409A1 (fr) 1992-04-03 1993-10-06 Ciba-Geigy Ag Dérivés de pyrimidine et procédé pour leur préparation
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US6894051B1 (en) 1997-07-18 2005-05-17 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
EP0998473A1 (fr) 1997-07-18 2000-05-10 Novartis AG Modification de la forme cristalline d'un derive n-phenyl-2-pyrimidineamine, procede de preparation et d'utilisation de ce dernier
AU740713B2 (en) 1997-07-18 2001-11-15 Novartis Pharma Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US20020115858A1 (en) 1997-07-18 2002-08-22 Juerg Zimmermann Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
WO1999003854A1 (fr) 1997-07-18 1999-01-28 Novartis Ag Modification de la forme cristalline d'un derive n-phenyl-2-pyrimidineamine, procede de preparation et d'utilisation de ce dernier
US7544799B2 (en) 1997-07-18 2009-06-09 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US20060173182A1 (en) 2003-02-18 2006-08-03 Cipla Limited Process of preparing imatinib and imatinib prepared thereby
US20050143389A1 (en) 2003-12-19 2005-06-30 Mount Sinai School Of Medicine Of New York University Treatment of hepatic fibrosis with imatinib mesylate
WO2006040779A2 (fr) 2004-10-11 2006-04-20 Natco Pharma Limited Formule à matrice flottante gastrique à libération contrôlée contenant la substance imatinib
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20090238884A1 (en) * 2008-03-21 2009-09-24 Elan Pharma International Limited Compositions for site-specific delivery of imatinib and methods of use
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PENG BIN ET AL: "Absolute bioavailability of imatinib (Glivec(R)) orally versus intravenous infusion.", JOURNAL OF CLINICAL PHARMACOLOGY, vol. 44, no. 2, February 2004 (2004-02-01), pages 158 - 162, XP009169976, ISSN: 0091-2700 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019021229A1 (fr) 2017-07-26 2019-01-31 Ftf Pharma Private Limited Formes galéniques liquides d'imatinib
CN111278466A (zh) * 2017-07-26 2020-06-12 夫特弗制药私人有限公司 伊马替尼的液体剂型
US20200206223A1 (en) * 2017-07-26 2020-07-02 Ftf Pharma Private Limited Liquid dosage forms of imatinib
AU2018306149B2 (en) * 2017-07-26 2021-09-16 Ftf Pharma Private Limited Liquid dosage forms of imatinib
US20220160709A1 (en) * 2017-07-26 2022-05-26 Ftf Pharma Private Limited Liquid dosage forms of imatinib
US11957681B2 (en) * 2017-07-26 2024-04-16 Shorla Pharma Limited Liquid dosage forms of Imatinib
WO2019162756A3 (fr) * 2018-02-20 2019-10-31 Ftf Pharma Private Limited Compositions pharmaceutiques liquides de médicaments anticancéreux
WO2021009686A1 (fr) 2019-07-15 2021-01-21 Intas Pharmaceuticals Ltd. Composition pharmaceutique d'imatinib
CN114306342A (zh) * 2020-09-30 2022-04-12 江苏先声药业有限公司 一种注射用伊马替尼盐的药物组合物及其制备方法

Similar Documents

Publication Publication Date Title
US10201519B2 (en) Stabilized pediatric suspension of carisbamate
EP2395979B1 (fr) Libération contrôlée, compositions orales de dosage contenant du cddo-me amorphe
US9801876B2 (en) Complex granule formulation having improved stability comprising levocetirizine and montelukast
NO20120203L (no) Farmasoytiske former med forbedrede farmakokinetiske egenskaper
US20210220363A1 (en) Methods for increasing sepiapterin plasma exposure
KR20100135316A (ko) 감칠맛을 가진 디페리프론용 액상 제제
WO2014041551A1 (fr) Formulation comprenant de l'imatinib sous la forme d'une solution orale
JP2011105694A (ja) オロパタジン経口固形組成物
WO2011136751A2 (fr) Composition pharmaceutique hydrosoluble
JP3899522B2 (ja) 苦味が低減されたプランルカスト水和物を含有する製剤
JP2008094751A (ja) プランルカスト水和物含有医薬組成物
US20050069584A1 (en) Diphenhydramine tannate solid dose compositions and methods of use
US11285152B2 (en) Stable oral pharmaceutical composition of imatinib
WO2014147631A1 (fr) Formulation comprenant du géfitinib comme suspension orale
US20100272800A1 (en) Orally disintegrating olanzapine tablet
US20230355588A1 (en) Methods and compositions for oral pilocarpine liquid
KR20130025851A (ko) 메게스트롤 속붕해정 및 이의 제조 방법
KR20220131186A (ko) L-세린 또는 이의 약제학적으로 허용가능한 염의 액상 제제 및 이의 제조방법
JP2006316051A (ja) 苦味が低減されたプランルカスト水和物を含有する製剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12784745

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12784745

Country of ref document: EP

Kind code of ref document: A1